146 related articles for article (PubMed ID: 28548552)
21. Increased serum VEGF and b-FGF in Graves' ophthalmopathy.
Ye X; Liu J; Wang Y; Bin L; Wang J
Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1639-44. PubMed ID: 24867311
[TBL] [Abstract][Full Text] [Related]
22. Peroxisome proliferator-activated receptor-gamma gene expression in orbital adipose/connective tissues is increased during the active stage of Graves' ophthalmopathy.
Mimura LY; Villares SM; Monteiro ML; Guazzelli IC; Bloise W
Thyroid; 2003 Sep; 13(9):845-50. PubMed ID: 14588098
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study.
Falkowski B; Szczepanek-Parulska E; Sawicka-Gutaj N; Krygier A; Ruchala M
Mediators Inflamm; 2020; 2020():4748612. PubMed ID: 32694926
[TBL] [Abstract][Full Text] [Related]
24. Evidence for enhanced Thy-1 (CD90) expression in orbital fibroblasts of patients with Graves' ophthalmopathy.
Khoo TK; Coenen MJ; Schiefer AR; Kumar S; Bahn RS
Thyroid; 2008 Dec; 18(12):1291-6. PubMed ID: 18976167
[TBL] [Abstract][Full Text] [Related]
25. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
[TBL] [Abstract][Full Text] [Related]
26. Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.
Sawicka-Gutaj N; Budny B; Zybek-Kocik A; Sowiński J; Ziemnicka K; Waligórska-Stachura J; Ruchała M
Endocrine; 2016 Aug; 53(2):497-504. PubMed ID: 26767650
[TBL] [Abstract][Full Text] [Related]
27. Role of macrophage infiltration in the orbital fat of patients with Graves' ophthalmopathy.
Chen MH; Chen MH; Liao SL; Chang TC; Chuang LM
Clin Endocrinol (Oxf); 2008 Aug; 69(2):332-7. PubMed ID: 18284633
[TBL] [Abstract][Full Text] [Related]
28. Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy.
Aass C; Norheim I; Eriksen EF; Børnick EC; Thorsby PM; Pepaj M
PLoS One; 2017; 12(4):e0175274. PubMed ID: 28419103
[TBL] [Abstract][Full Text] [Related]
29. Altered Expression of CXCL13 and Its Chemokine Receptor CXCR5 on B Lymphocytes during Active Graves' Orbitopathy.
Wan S; Lin M; Mao Y; Chen X; Liang D
Curr Eye Res; 2021 Feb; 46(2):210-216. PubMed ID: 32643429
[TBL] [Abstract][Full Text] [Related]
30. Markers of inflammation and fibrosis in the orbital fat/connective tissue of patients with Graves' orbitopathy: clinical implications.
Pawlowski P; Reszec J; Eckstein A; Johnson K; Grzybowski A; Chyczewski L; Mysliwiec J
Mediators Inflamm; 2014; 2014():412158. PubMed ID: 25309050
[TBL] [Abstract][Full Text] [Related]
31. Association between Clinical Activity Score and Serum Interleukin-6, Interleukin-8 and Interleukin-10 during Systemic Glucocorticoid Treatment for Active Moderate-to-Severe Graves' Orbitopathy.
Stoynova MA; Shinkov AD; Georgiev GK; Kovatcheva RD
Curr Eye Res; 2021 Oct; 46(10):1503-1508. PubMed ID: 33849364
[No Abstract] [Full Text] [Related]
32. Genetic Profiling of Orbital Fibroblasts from Patients with Graves' Orbitopathy.
Rotondo Dottore G; Bucci I; Lanzolla G; Dallan I; Sframeli A; Torregrossa L; Casini G; Basolo F; Figus M; Nardi M; Marcocci C; Marinò M
J Clin Endocrinol Metab; 2021 Apr; 106(5):e2176-e2190. PubMed ID: 33484567
[TBL] [Abstract][Full Text] [Related]
33. Serum interleukin-16 and RANTES during treatment of Graves' orbitopathy with corticosteroids and teleradiotherapy.
Mysliwiec J; Palyga I; Nikolajuk A; Kowalska A; Gorska M
Endokrynol Pol; 2012; 63(2):92-6. PubMed ID: 22538746
[TBL] [Abstract][Full Text] [Related]
34. Relationship between serum cholesterol and Graves' orbitopathy (GO): a confirmatory study.
Lanzolla G; Sabini E; Profilo MA; Mazzi B; Sframeli A; Rocchi R; Menconi F; Leo M; Nardi M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2018 Dec; 41(12):1417-1423. PubMed ID: 29923059
[TBL] [Abstract][Full Text] [Related]
35. Soluble CTLA-4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms.
Daroszewski J; Pawlak E; Karabon L; Frydecka I; Jonkisz A; Slowik M; Bolanowski M
Eur J Endocrinol; 2009 Nov; 161(5):787-93. PubMed ID: 19734241
[TBL] [Abstract][Full Text] [Related]
36. Search of reference biomarkers reflecting orbital tissue remodeling in the course of Graves' orbitopathy.
Pawlowski P; Poplawska I; Mysliwiec J; Dik WA; Eckstein A; Berchner-Pfannschmidt U; Milewski R; Lawicki S; Dzieciol-Anikiej Z; Rejdak R; Reszec J
Folia Histochem Cytobiol; 2020; 58(1):37-45. PubMed ID: 32176314
[TBL] [Abstract][Full Text] [Related]
37. Expression of cyclooxygenase-2 in orbital fibroadipose connective tissues of Graves' ophthalmopathy patients.
Konuk EB; Konuk O; Misirlioglu M; Menevse A; Unal M
Eur J Endocrinol; 2006 Nov; 155(5):681-5. PubMed ID: 17062883
[TBL] [Abstract][Full Text] [Related]
38. Disturbances of modulating molecules (FOXP3, CTLA-4/CD28/B7, and CD40/CD40L) mRNA expressions in the orbital tissue from patients with severe graves' ophthalmopathy.
Pawlowski P; Wawrusiewicz-Kurylonek N; Eckstein A; Reszec J; Luczynski W; Johnson K; Kretowski A; Bakunowicz-Lazarczyk A; Gorska M; Szamatowicz J; Chyczewski L; Mysliwiec J
Mediators Inflamm; 2015; 2015():340934. PubMed ID: 25653477
[TBL] [Abstract][Full Text] [Related]
39. Oxidative stress markers in tears of patients with Graves' orbitopathy and their correlation with clinical activity score.
Choi W; Li Y; Ji YS; Yoon KC
BMC Ophthalmol; 2018 Nov; 18(1):303. PubMed ID: 30463536
[TBL] [Abstract][Full Text] [Related]
40. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
Woo YJ; Jang SY; Lim TH; Yoon JS
Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
